ArticleReviews in cardiovascular medicine2025
Unraveling the Genetic Links: The Impacts of Antidiabetic Drugs on Stroke Risk.
Article in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Explore the Causal Effect of SGLT2 Inhibition on Venous Thromboembolism Events: A Drug-Target Mendelian Randomization Study With Pharmacovigilance Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes is widely recognized as a major contributor to stroke risk. Certain antidiabetic medications have demonstrated promising effects on reducing stroke incidence and improving outcomes. Methods: To evaluate the potential impacts of antidiabetic drugs comprehensively, we developed an analytical framework that incorporates summary-based Mendelian randomization (SMR), two-sample Mendelian randomization (TSMR), and colocalization analyses. Summary statistics from the largest genome-wide association study (GWAS) of stroke and known subtypes were utilized, along with gene expression data from the blood, aorta, coronary artery, and tibial artery provided by the eQTLGen or GTEx V8 consortia. Results: Elevated expression levels of the solute carrier family 5 member 2 ( Conclusion: Our findings suggest that SGLT2 inhibitors and sulfonylureas may influence the risk of AIS. Additionally, activation of the insulin receptor may reduce the risk of LAS. These results increase our understanding of medication options for stroke patients who require hypoglycemic agents and provide a basis for the strategic repurposing of antidiabetic drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.